A Phase 1, Double-Blind, Placebo-Controlled Study to Assess the Safety and Immunogenicity of MVA3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Vaccinia-Naive Human Immunodeficiency Virus (HIV)-Seropositive Subjects

Trial Profile

A Phase 1, Double-Blind, Placebo-Controlled Study to Assess the Safety and Immunogenicity of MVA3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Vaccinia-Naive Human Immunodeficiency Virus (HIV)-Seropositive Subjects

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 21 Jan 2014

At a glance

  • Drugs Smallpox vaccine (Primary)
  • Indications Smallpox
  • Focus Adverse reactions
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 06 Jan 2009 Planned number of patients changed from 405 to 2 as reported by ClinicalTrials.gov.
    • 06 Jan 2009 Actual end date (Jul 2007) added as reported by ClinicalTrials.gov.
    • 02 Dec 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top